Sedia Biosciences Corporation announces expansion and move to new research and manufacturing facility in Beaverton, Oregon, USA
Txylo.com/10082641
Trending...
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award
- San Antonio: District 2 Councilwoman Jada Andrews-Sullivan's Statement on Ongoing Vaccine Clinic at the Alamodome
- "Ready To Love" Cast Member & Fitness Guru Tony Stubbs Releases New "7 Minute" Fitness Video
Expansion accommodates significant growth in demand for its new rapid point-of-care HIV tests intended to break the chain of new HIV infections worldwide
BEAVERTON, Ore. - Txylo -- Sedia Biosciences Corporation, formerly of Portland Oregon, today announced the relocation to and opening of their new assay development and manufacturing facility in Beaverton, Oregon. The 27,000 square foot facility provides for both current growth as well as additional near-term expansion and enables immediate scale-up of manufacturing capacity as well as research capabilities. Equipped with multiple state of the art, environmentally controlled production, quality and research laboratories, high throughput production equipment, and expanded warehouse capacity, the facility is also designed to accommodate the "new normal" of business in a pandemic challenged environment. The new facility will have a much needed immediate impact on production capacity of Sedia's products, now being used in partnership with the U.S. Centers for Disease Control and Prevention (CDC, www.cdc.gov), PEPFAR (President's Emergency Plan for AIDS Relief, www.pepfar.gov), and other NGOs and stakeholders working with Sedia.
More on Txylo.com
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on Txylo.com
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
More on Txylo.com
- Thirteen MBK Senior Living Communities Receive "2021 Best of Senior Living" Distinction
- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
- San Antonio: District 2 Councilwoman Jada Andrews-Sullivan's Statement on Ongoing Vaccine Clinic at the Alamodome
- Real-Time Social Music App EarBuds & Bose Encourage Fans to "Listen Like a Pro" Ahead of Divisional Playoff Game
- Huntsman Completes the Acquisition of Gabriel Performance Products, Further Expanding its Specialty Chemicals Portfolio
Dr. Ronald Mink, Chief Science Officer and President, who co-founded Sedia with Roger Gale, Sedia's CEO and Chairman, stated that "Sedia has been focused on fulfilling the growing demand from CDC, PEPFAR and others for our AsantéTM HIV Rapid Recency® Assay. This test is the first rapid point-of-care assay with the capability to both quickly verify HIV status of a patient, and determine if they are a recent, or 'new' infection. Public Health agencies worldwide use this valuable information to identify where new outbreaks of HIV are occurring. Tracking these early cases is important as they have the highest likelihood of transmitting HIV and may be doing so unknowingly. Such individuals can be the source of new and sudden outbreaks of the disease. Our products are intended to break this cycle. COVID has shown that what the world needs is simple, fast and accurate diagnostic tests in large numbers. This is what we do. Sedia is dynamic, growing rapidly and is very relevant to the current global health crisis."
According to Nancy Lime, Vice President Operations, "Globally, an estimated 19% of persons living with HIV are unaware of their status. Individuals with recent HIV infections can be responsible for up to 40% of new infections in their community. Since HIV can remain asymptomatic and undetected for months, recently infected individuals can continue to pass the virus to others. New approaches and tools are needed to fight HIV and other global pandemics and this technology can potentially be applied to other diseases, including the SARS-CoV-2 'COVID-19' virus and sexually transmitted diseases."
More on Txylo.com
- La Prensa Texas Heads to Washington D.C. Digital Coverage of the Inauguration of 46th President
- San Antonio: Councilwoman Sandoval Appointed to Serve on National League of Cities' Transportation & Infrastructure Services Committee
- Aspen Dental Expands Access to Dental Care in Burleson, Texas With Opening Of 43rd Practice in State
- AUA College of Medicine Establishes Admissions Agreement with Mississippi Valley State University
- Dollyhood Records Signs Distribution Deal With Sony!
About Sedia Biosciences Corporation
Sedia Biosciences is a privately held medical device and diagnostics company founded in 2009 and is based in Beaverton, Oregon, USA. Our commitment is to become a leader in three areas intended to advance global access to care: (1) state-of-the-art rapid point-of-care diagnostic assays, (2) novel epidemiological disease surveillance assays and other Public Health tools and (3) innovative clinical specimen collection devices to improve and facilitate remote collection of specimens for follow-up testing. Sedia brings together a dedicated team of scientists and business people that share a common mission: to improve access to medical care around the world by providing innovative diagnostic, epidemiological and clinical products.
Follow us on Facebook, LinkedIn, Twitter or at our website: www.sediabio.com
Source: Sedia Biosciences Corporation
Filed Under: Health
0 Comments
Latest on Txylo.com
- "Diamond Fuji" to be Seen from TOKYO SKYTREE in February
- Q4 2020 | Houston Office | Research & Forecast Report
- San Antonio: City announces Martin Luther King Jr. holiday schedule of City services
- Jake L Kelly, Esq. The quiet Mogul
- Texas First State To Administer 1 Million COVID-19 Vaccines
- Working Solutions Places 4th Among FlexJobs' 2021 Top 100 Companies With Remote Jobs
- Snow Software Recognized as a 2020 Gartner Peer Insights Customers' Choice for Software Asset Management
- Governor Abbott Appoints Six To Texas Medical Board District Four Review Committee
- Governor Abbott Appoints Seven To Texas Medical Board District Three Review Committee
- Texpak Offers Environmentally-Friendly Ecotach™ Fasteners to Address Sustainability Needs
- Houston City Council Approves Largest Brownfield Solar Project in the Nation
- Hedera21 Hackathon: Call for Developers to Build the Future of Asset Tokenization, Beginning January 19th, 2021
- Chevron Invests in Carbon Capture and Utilization Startup
- Morningstar names Quantified STF Fund top-performing tactical-allocation fund in 2020
- Atos launches Unify Office by RingCentral in U.S.
- Mayor Turner, Houston Public Library, and Mayor's Office of Cultural Affairs Announce Search for Houston's Next Poet Laureate
- Edgile Releases ServiceNow Automated Regulatory Compliance (ArC) for 2021
- KBR Furthers Sustainability Commitment with Innovative Plastics Recycling Process in Alliance with Mura Technology
- Paysafe: Payments crucial to ongoing growth of US online sports-betting market
- Financial Solutions Inc. Receives the 2020 Best of Sheridan Wyoming Award